Regulation in the Regenerative Medicine Industry (Webinar #3) – Dec 2016

By December 19, 2016

Regulation in the Regenerative Medicine Industry (Webinar #3) – Dec 2016
PAP 2016-17

 
 
00:00 / 02:05:28
 
1X
 

Session 3: Regulation in the Regenerative Medicine Industry (Webinar)

The talks of this session were given by Dr Julian Hitchcock from Denoon Legal, and Dr Christopher Bravery from Consulting on Advanced Biologics.

The legal framework for market approval in Europe is provided by EU directives and regulations. There are two fundamental pieces of regulation for ATMPs: The European Tissue and Cells Directive (EUTCD) [Directive 2004/23/EC and implementing directives] and the Advance Therapy Medicinal Product (ATMP) Regulations (1394/2007 and 668/2009). European Medicines Agency and its Committee for Advanced Therapies (CAT) are the two most relevant regulatory bodies. A product may be an ATMP scientifically, but legally it may not be so. ATMP classification can be sought from CAT. Market authorisation can be sought nationally, through mutual recognition in a number of states, or centralised in the EU through the European Medicines Agency.

Speakers:

Dr. Julian Hitchcock
Counsel
Denoon Legal

Dr. Christopher Bravery
Director
Consulting on Advanced Biologicals Ltd

Links mentioned:

———-

We would like to thank our sponsors, PROTiP Medical & Immodgel.

Contact us at info@termisbpc.org
For more information, please visit http://www.termisbpc.org/pre-accelerator

Leave a Reply